☆ 4.8 Article

Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Immunology

LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation

Clifford Guy et al.

Summary: This study reveals that the inhibitory receptor LAG3 interferes with TCR signaling and T cell activation by lowering the pH at the immune synapse, providing insights into the mechanism of action of LAG3 in inhibiting T cell function.

NATURE IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

Takayuki Matsumae et al.

Summary: This study investigated the potential of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) as biomarkers for predicting the therapeutic outcome in u-HCC patients treated with anti-programmed cell death1-ligand1 (PD-L1)/vascular endothelial growth factor (VEGF) therapy. Patients with high levels of cfDNA showed poorer response rates and shorter survival compared to those with low levels of cfDNA. The most frequently mutated genes in ctDNA were telomerase reverse transcriptase (TERT), tumor protein 53 (TP53), and catenin beta 1 (CTNNB1). A TERT ctDNA mutation and high alpha-fetoprotein (AFP) level were independent predictors of poorer overall survival. cfDNA/ctDNA profiling may be useful for predicting the therapeutic outcome in u-HCC patients treated with Atezo/Bev therapy.

CANCERS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups

Matthias Pinter et al.

Summary: Studies on the application of ICBs in HCC patients are growing, but there are still challenges in patient selection. Combination therapy may show better efficacy in some cases, but caution is needed for specific patient populations.

GUT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Johann von Felden et al.

Summary: This study reveals the mutational landscape of advanced HCC and identifies predictive biomarkers for response to systemic therapies. Mutations in the PI3K/MTOR pathway are associated with shorter PFS after tyrosine kinase inhibitor treatment, while WNT pathway mutations are not predictive of response after CPI therapy.

ONCOGENE (2021)

Add to Collection

Article Medicine, Research & Experimental

Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes

Xinyu Gu et al.

Summary: A novel five-gene-based prognostic model was established based on the tumor immune microenvironment to predict immunotherapy efficacy in HCC patients. This model can stratify patients into low-risk and high-risk groups, with the high-risk group exhibiting worse prognosis and lower sensitivity to immunotherapy compared to the low-risk group. Functional enrichment analysis identified potential associations of the five genes with metabolic processes and oncological signatures.

JOURNAL OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

Ming Lei et al.

Summary: This study indicates a stronger association between PD-L1 expression determined by CPS and efficacy of immune checkpoint inhibitors in patients with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC). Inflammatory signatures are also correlated with response to this therapy, suggesting the need for further investigation.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Meeting Abstract Oncology

Relatlimab plus nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073

B. Sangro et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Integrated analysis of multimodal single-cell data

Yuhan Hao et al.

Summary: The study introduces a weighted-nearest neighbor analysis framework to learn the relative utility of each data type in each cell, enabling integrative analysis of multiple modalities. Applied to a CITE-seq dataset, the method constructs a multimodal reference atlas of the circulating immune system and successfully identifies and validates previously unreported lymphoid subpopulations.

CELL (2021)

Add to Collection

Meeting Abstract Oncology

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Evan J. Lipson et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Cell Biology

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

Ronglai Shen et al.

Summary: Blood-based immune profiling was used to identify three distinct immune phenotypes associated with response to immune checkpoint blockade treatment in melanoma patients, with LAG(+) immunotype showing poorer outcomes. This LAG(+) immunotype was also validated to be significantly associated with treatment response and survival in an independent cohort of patients with urothelial carcinoma. The study suggests potential for using pretreatment LAG(+) immunotype as a marker for identifying patients less likely to benefit from immune checkpoint blockade and to guide further investigations of actionable immune targets.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy

Kimiharu Takamatsu et al.

Summary: Targeting inhibitory receptors (IRs) LAG-3, TIM-3, and TIGIT in immunotherapy for human renal cell carcinoma is promising, with individual IR levels serving as potential biomarkers for analysis. The immunogenomic landscape of the disease can be investigated through automated single-cell counting for these IRs.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis

Xiaozhan Zhang et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2020)

Add to Collection

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Correlation Between Tumor-Associated Macrophage and Immune Checkpoint Molecule Expression and Its Prognostic Significance in Cutaneous Melanoma

Young Jae Kim et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Bruno Sangro et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis

Mengzhou Guo et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Review Oncology

Progress of immune checkpoint LAG-3 in immunotherapy

Chanchan Shan et al.

ONCOLOGY LETTERS (2020)

Add to Collection

Article Oncology

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

Harry Ho Man Ng et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Gastroenterology & Hepatology

Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors

Paul Winograd et al.

HEPATOLOGY COMMUNICATIONS (2020)

Add to Collection

Article Oncology

Prognostic value of CD8+PD-1+immune infiltrates and PDCD1 gene expression in triple negative breast cancer

Joe Yeong et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

David J. Pinato et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

Lynn G. Feun et al.

CANCER (2019)

Add to Collection

Review Gastroenterology & Hepatology

Immunotherapy for hepatocellular carcinoma: Current and future

Michael P. Johnston et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Oncology

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma

Yi Zheng et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

T Yau et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Genomic analyses and immunotherapy in advanced melanoma

F. Stephen Hodi et al.

CANCER RESEARCH (2019)

Add to Collection

Article Oncology

LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival

Yi Que et al.

CANCER BIOLOGY & MEDICINE (2019)

Add to Collection

Article Oncology

Hepatocellular carcinoma in the era of immunotherapy

Hao-Wen Sim et al.

CURRENT PROBLEMS IN CANCER (2018)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Pathology

An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use

Jeffrey Chun Tatt Lim et al.

PATHOLOGY (2018)

Add to Collection

Article Medicine, Research & Experimental

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Add to Collection

Article Oncology

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

Yayi He et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B A balance between immunity strength and liver injury extent

Bo Ye et al.

MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities

Pegah Golabi et al.

MEDICINE (2017)

Add to Collection

Letter Medicine, General & Internal

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

Mark Yarchoan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Characterization of the Immune Microenvironment in Hepatocellular Carcinoma

Mark Yarchoan et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Tumour heterogeneity poses a significant challenge to cancer biomarker research

Karolina Cyll et al.

BRITISH JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer

Joe Yeong et al.

BREAST CANCER RESEARCH AND TREATMENT (2017)

Add to Collection

Article Oncology

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma

Wei-Wei Deng et al.

ONCOIMMUNOLOGY (2016)

Add to Collection

Review Gastroenterology & Hepatology

Hepatitis C virus-induced hepatocellular carcinoma

Nicolas Goossens et al.

CLINICAL AND MOLECULAR HEPATOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

Zhengyan Kan et al.

GENOME RESEARCH (2013)

Add to Collection

Article Immunology

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

Fu-Jun Li et al.

IMMUNOLOGY LETTERS (2013)

Add to Collection

Article Oncology

STAT1 negatively regulates hepatocellular carcinoma cell proliferation

Guofu Chen et al.

ONCOLOGY REPORTS (2013)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Multidisciplinary Sciences

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

V Shankaran et al.

NATURE (2001)

Add to Collection

Article Biochemistry & Molecular Biology

Serine phosphorylation of STATs

T Decker et al.

ONCOGENE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.